Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Gains from Sales and Divestitures: 2016-2025

Historic Gains from Sales and Divestitures for Tg Therapeutics (TGTX) over the last 8 years, with Sep 2025 value amounting to $1.8 million.

  • Tg Therapeutics' Gains from Sales and Divestitures fell 3.36% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 3.36%. This contributed to the annual value of $2.3 million for FY2024, which is 9.91% down from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Gains from Sales and Divestitures is $1.8 million, which was up 12.86% from $1.6 million recorded in Q2 2025.
  • Tg Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $6.3 million during Q4 2022, with a 5-year trough of $682,840 in Q1 2021.
  • In the last 3 years, Tg Therapeutics' Gains from Sales and Divestitures had a median value of $1.8 million in 2025 and averaged $1.8 million.
  • Per our database at Business Quant, Tg Therapeutics' Gains from Sales and Divestitures spiked by 382.98% in 2022 and then crashed by 60.26% in 2023.
  • Tg Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $1.3 million in 2021, then surged by 382.98% to $6.3 million in 2022, then plummeted by 60.26% to $2.5 million in 2023, then fell by 9.91% to $2.3 million in 2024, then decreased by 3.36% to $1.8 million in 2025.
  • Its Gains from Sales and Divestitures stands at $1.8 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.4 million for Q1 2025.